Follicular Fluid Fetuins in in Vitro Fertilization
Follicular Fetuin A and Fetin B Levels Are Associated With Clinical Pregnancy and Live Birth Rates in IVF Cycles
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Samsun, Turkey, 55000
- Samettin Çelik
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Poor ovarian reserve patients and patient with polycystic ovary syndrome
Exclusion Criteria:
Normoresponders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Infertile women with normal ovarian reserve
Infertile women with normal ovarian reserve will be included.
|
Serum Fetuin A and fetuin B
Other Names:
|
|
ACTIVE_COMPARATOR: Infertile women with high ovarian reserve
Infertile women with high ovarian reserve will be included.
|
Serum Fetuin A and fetuin B
Other Names:
|
|
ACTIVE_COMPARATOR: Infertile women with poor ovarian reserve
Infertile women with poor ovarian reserve will be included.
|
Serum Fetuin A and fetuin B
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
he primary outcome of this study is to measure the follicüler fluid concentrations of fetuin A and fetuin B in IVF cycles. Follicular fluid Fetuin A and Fetuin B will be measured during oosit pick up in IVF cycles.
Time Frame: 4 weeks
|
The relationship between fetuin A and insulin resistance suggests the probable role of this glycoprotein in human fertility.
Fetuin B prevents the hardening of zona pellucida by inhibiting ovastacin.In this study, follicular fluid concentrations of fetuin A and fetuin B are measured in IVF cycles
|
4 weeks
|
|
The secondary goal of this study is to whether follicular fluid concentrations of fetuin A and fetuin B are associated with clinical pregnancy and live birth rates in IVF cycles.
Time Frame: 8 weeks
|
The oocyte fluid samples that are derived from the largest follicles and contained oocytes are collected for the measurement of fetuin A and fetuin B concentrations.
Follicular fluid samples are centrifuged at 3000 g for 10 minutes and stored at -80ºC up to the working day.
On the working day, samples are brought to room temperature.
The fertilized embryos are transferred into the uterine cavity on the 2nd day.A pregnancy test is performed on the 12th day following embryo transfer, hCG-positive patients undergot transvaginal ultrasound scan on 21st day for detection of clinical pregnancy.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KAEK-2019/4/27
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
NCT01936077CompletedInfertility, Female Infertility, Male Infertility
-
NCT00315029CompletedPregnancy | Male Infertility | Female Infertility
-
NCT02107521TerminatedMale Infertility | Female Infertility
-
NCT03670758UnknownUnexplained Female Infertility
-
NCT04945265Not yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
NCT03323801CompletedMale Infertility, Azoospermia
-
NCT01331395TerminatedPrimary Female Infertility | Secondary Female Infertility
-
NCT01859520CompletedMale Infertility | Unexplained Infertility
-
NCT07611448Enrolling by invitationInfertility (IVF Patients) | Infertility Assisted Reproductive Technology
-
NCT07337265Not yet recruitingMale Infertility | Unexplained Infertility | Sperm DNA Fragmentation
Clinical Trials on Serum test
-
NCT07154004CompletedNo Protrusion | No Open Wound | No Severe Allergic Reaction | No Scar | No Tattoo | No Significant Skin Defect
-
NCT04363593CompletedCorona Virus Infection
-
NCT05500027RecruitingPancreatic Cancer | Serum Biomarker
-
NCT06606223Not yet recruiting
-
NCT01091402CompletedUrticaria | Respiratory Allergic Diseases
-
NCT05801822Not yet recruitingSubclinical Hypothyroidism
-
NCT03205020Unknown
-
NCT06416995RecruitingPreterm Birth | Fetal Growth Retardation | Preeclampsia | Gestational Diabetes | Gestational Hypertension
-
NCT03954288UnknownCholesteatoma | Otitis Media Chronic
-
NCT06108557Not yet recruiting